Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › PMVP

PMV Pharmaceuticals

PMVP Lead: Phase 2 6 Biotech Distilled articles ↓ 24 filings & releases ↓ Cash $12.5M (Jun 30, 2026) ↓ 6 verdicts ↓ 3 timing quotes ↓
Oncology Small Molecule

Market cap $67.4M 53.5M shares (10-Q, Aug 14, 2026) × $1.26 close Nov 6, 2026

Most recent annual filing: 2026-03-06

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Rezatapopt toplineNov 20, 2026Rezatapopt topline, Nov 20, 2026, thesis-defining
  2. Rezatapopt NDA filing1Q 2027Rezatapopt NDA filing, 1Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

Precision Oncology Platform

Small molecule discovery and development platform targeting p53 mutations and p53-related cancers; leverages structural biology, assays, and biomarkers to identify and optimize selective small molecules that structurally correct specific mutant p53 proteins to restore wild-type function; disease focus is tumor-agnostic oncology defined by p53 genomic alterations.

Targets: p53

Capital (as filed)

Cash
$12.5M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$67.0M Jun 30, 2026
Operating cash flow
−$14.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$79.4M cash, runway Q1 2027 per the update of Sep 1, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on PMV Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-02-16 Watch PMV Pharmaceuticals (PMVP): Scientific Deep Dive for Rezatapopt The science is compelling but a critical dilution gap and precarious balance sheet make the equity a hold until the company fortifies its balance sheet via a secondary offering.
  2. 2026-03-08 Watch UPDATE: PMV Pharma (PMVP) - The Data Gets Stronger... ORR improved to 50% and Orphan Drug Designation was granted, but OrbiMed's full liquidation and the ongoing dilution overhang keep the equity on the sidelines until the balance sheet is addressed.
  3. 2026-05-12 Watch UPDATE: PMV Pharma (PMVP) - The ORR Shrinks, The NEJM Validates, The Clock Tightens ORR drifted down to 44% as the denominator grew and a dilutive raise is now a mathematical certainty, but NEJM validation and durable responses keep the science thesis intact — waiting for the post-raise entry.
  4. 2026-08-15 Watch UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Goes Up Auditors issued a formal going-concern warning while PYNNACLE enrollment completed, but buying before the inevitable raise means paying for a capital structure that does not yet exist.
  5. 2026-08-31 Speculative buy speculative UPDATE: PMV Pharma (PMVP) - The Raise Finally Comes, Wrapped in Warrants The long-awaited financing event is underway, duration of response improved to 10.0 months, and the ORR stabilized — the overhang is being cleared, warranting a speculative buy once final offering terms are confirmed.
  6. 2026-09-02 Speculative buy speculative UPDATE: PMV Pharma (PMVP) - The Blanks Get Filled In The offering priced at market ($1.21, no discount), oversubscribed, providing ~$110M pro forma cash through the Q1 2027 NDA — the capital structure now exists and the prior objection to buying is retired.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)